These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30368914)

  • 1. Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches.
    Vetel S; Sérrière S; Vercouillie J; Vergote J; Chicheri G; Deloye JB; Dollé F; Bodard S; Tronel C; Nadal-Desbarats L; Lefèvre A; Emond P; Chalon S
    Synapse; 2019 Mar; 73(3):e22077. PubMed ID: 30368914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
    Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
    Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
    Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
    Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
    Pain S; Vergote J; Gulhan Z; Bodard S; Chalon S; Gaillard A
    Fundam Clin Pharmacol; 2019 Oct; 33(5):544-548. PubMed ID: 30866091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
    Maia S; Arlicot N; Vierron E; Bodard S; Vergote J; Guilloteau D; Chalon S
    Synapse; 2012 Jul; 66(7):573-83. PubMed ID: 22337286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Treatment with the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis BB12 Attenuates Motor Impairment, Striatal Microglial Activation, and Dopaminergic Loss in Rats with 6-Hydroxydopamine-induced Hemiparkinsonism.
    Cuevas-Carbonell SG; Vásquez-Celaya L; García-López D; Granados-Patrón D; García-Miss MDR; Álvarez-Cervera FJ; Mut-Martín M; Parra I; Mendieta L; Salgado H; Alamilla J; Cruz-Bojórquez R; Ávila-Escalante ML; Aranda-González II; Góngora-Alfaro JL
    Neuroscience; 2022 Dec; 507():79-98. PubMed ID: 36370934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
    Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
    J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
    Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats.
    Matheus FC; Rial D; Real JI; Lemos C; Takahashi RN; Bertoglio LJ; Cunha RA; Prediger RD
    Mol Neurobiol; 2016 Aug; 53(6):3891-3899. PubMed ID: 26164273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions.
    Kumar V; Singh BK; Chauhan AK; Singh D; Patel DK; Singh C
    Mol Neurobiol; 2016 Jul; 53(5):2761-2777. PubMed ID: 25764516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease.
    Casteels C; Lauwers E; Bormans G; Baekelandt V; Van Laere K
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):124-34. PubMed ID: 17906859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
    Stott SRW; Barker RA
    Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
    Hernandes MS; Santos GD; Café-Mendes CC; Lima LS; Scavone C; Munhoz CD; Britto LR
    PLoS One; 2013; 8(9):e75532. PubMed ID: 24086556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are striatal tyrosine hydroxylase interneurons dopaminergic?
    Xenias HS; Ibáñez-Sandoval O; Koós T; Tepper JM
    J Neurosci; 2015 Apr; 35(16):6584-99. PubMed ID: 25904808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET Imaging of Serotonin Transporters With 4-[(18)F]-ADAM in a Parkinsonian Rat Model With Porcine Neural Xenografts.
    Chiu CH; Li IH; Weng SJ; Huang YS; Wu SC; Chou TK; Huang WS; Liao MH; Shiue CY; Cheng CY; Ma KH
    Cell Transplant; 2016; 25(2):301-11. PubMed ID: 25994923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.